Skip to main content

Longwood Fund-founded TScan starts trading on Nasdaq, shares drop

After pricing shares at the low end of its range, cancer drug developer TScan Therapeutics still saw shares drop in its first day on the Nasdaq. TScan is the 12th local biotech to make a public debut this year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.